Pharma & Biotech Insights, Interviews & Features
Biotechnology
11 November 2024 11 November 2024
Today's issue
Refine Search
Biotechnology
Despite a range of online resources to facilitate interactions between attendees, there clearly won’t be the same opportunities for networking at this year’s annual congress of the European Society of Medical Oncology (ESMO). 15 September 2020
Pharmaceutical
Encouraged by China’s moves on to pushing innovative drug development in recent years, multinationals have quickly adjusted their R&D games in the country, said speakers from multinational corporations (MNCs) at a forum about innovative drugs held by the Shanghai-based consulting firm PharmaDJ in in Shanghai, reports The Pharma Letter’s local correspondent. 14 September 2020
Biotechnology
Despite rapid advances in the field of immuno-oncology that have transformed the cancer treatment landscape, many cancer patients are still left behind. Not every person has access to innovative therapies designed specifically to treat his or her disease. Many currently available immuno-oncology-based approaches and chemotherapies have brought long-term benefits to some patients—but many patients still need other therapeutic options. 10 September 2020
Pharmaceutical
Advanced manufacturing uses innovative manufacturing technologies to address medication shortages, improve drug quality, and accelerate time to market. Many outdated manufacturing processes are still being used in the manufacture of modern medical products, increasing the risk of product shortages, inflating the scale of production and thus product costs, and decreasing resilience to disruption during public health emergencies. 8 September 2020
Pharmaceutical
Just six months into the deadliest global pandemic for a century, the way we live has changed dramatically, most likely forever. For all of us, our children, yours, and mine, above all there will a pre- and post- COVID-19 world. 7 September 2020
Biosimilars
China’s Fosun Pharma’s biotech arm Henlius, best known for its biosimilars capability, is setting its sights on novel drug development, said Henlius chief executive Scott Liu at a recent press meeting in Shanghai. 4 September 2020
Pharmaceutical
The annual congress of the European Society of Medical Oncology (ESMO) will look a lot different this time, but that does not mean the data will be any less impactful. 4 September 2020
Pharmaceutical
Foreign drugs continue to disappear from the Russian pharmaceutical retail, posing a threat of a shortage of medicines that could be recommended for the treatment of some serious diseases, according to recent studies prepared by some local market research agencies and pharmaceutical business analysts, reports The Pharma Letter’s local correspondent. 1 September 2020
Pharmaceutical
In these times especially, but far from exclusively, security of supply remains one of the biggest challenges for pharmaceuticals manufacturers, writes Justin Eames, senior manager, APM Solution Consulting, Aspen Technology, in an Expert View. 27 August 2020
Pharmaceutical
China made the marketing authorization holder (MAH) scheme official in the country in December last year after running it as a three-year pilot program. The move was largely welcomed by China’s pharma industry, especially start-ups which have the research capacity but lack the funds to build a manufacturing facility. 25 August 2020
Pharmaceutical
Russia is interested in launching production of its vaccine against COVID-19 in Brazil at the facilities of some of local drugmakers, according to Kirill Dmitriev, head of the Russian Fund of Direct Investments (RFDI), one of Russia’s leading public investment funds and which participated in the project, reports The Pharma Letter’s local correspondent. 25 August 2020
Pharmaceutical
One of Russia’s largest blood plasma fractionation plant will soon be built in the Tatarstan Republic, one of Russia’s most economically developed regions, by the Israeli biotech and pharmaceutical company Alishech, according to recent statements, made by representatives of the investor and representatives of the Russian federal government, reports The Parma Letter’s local correspondent. 25 August 2020
Pharmaceutical
Media headlines are full of hope for potential vaccines and treatments to target SARS-CoV-2, the virus that causes the novel coronavirus disease COVID-19, writes Kate Shaw, the chief executive of UK-based clinical trials patient recruitment company Innovative Trials, in an Expert View. 21 August 2020
Pharmaceutical
Given the lack of Phase III data, it is not surprising that some international media reports reacted with skepticism to Russia’s approval of the so-called Sputnik V vaccine for COVID-19 last week. 20 August 2020
Biotechnology
Insights from Jeevan Virk, UK and Ireland general manager of Advanced Accelerator Applications. 18 August 2020
Pharmaceutical
Pierre-Georges Roy, partner at M&A advisor Results International, provides an Expert View on why deals kept being made even as much of society shut down. 18 August 2020
Pharmaceutical
Russia aims to take up 25% of global the COVID-19 vaccine market with its new vaccine within the next several years, according to recent statements by some senior officials of the country’s Ministry of Health and local pharmaceutical business analysts, reports The Pharma Letter’s local correspondent. 18 August 2020
Pharmaceutical
As the Indian government works on a comprehensive national policy on rare diseases, involved organizations have urged the Health Ministry to create a special fund and exempt the medicines and equipment required for treatment from import duties. 17 August 2020
Pharmaceutical
In what could be a major decision, the Indian government is looking to tweak an existing provision that allows new medicines developed by foreign companies to be exempt from price control for five years. 15 August 2020
Generics
Leading Russian public associations representing the interests of patients, together with local pharma sector analysts, have again criticized the currently implemented import substitution state policy in the domestic drug market, reports The Pharma Letter’s local correspondent. 11 August 2020
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze